Company Description
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.
It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs.
The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026.
Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 119 |
| CEO | Jian Irish |
Contact Details
Address: 5959 Horton Street, 7th Floor Emeryville, California 94608 United States | |
| Phone | 510 871 4880 |
| Website | metagenomi.co |
Stock Details
| Ticker Symbol | MGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001785279 |
| CUSIP Number | 59102M104 |
| ISIN Number | US59102M1045 |
| Employer ID | 81-3909017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jian Irish M.B.A., Ph.D. | Chief Executive Officer, President and Director |
| Dr. Brian Charles Thomas Ph.D. | Co-Founder and Director |
| Pamela M. Wapnick M.B.A. | Chief Financial Officer |
| Dr. Joseph Knowles M.D. | Co-Founder and Member of Scientific Advisory Board |
| Mark Leonard | Senior Vice President of Technical Development and Operations |
| Matthew L. Wein J.D. | General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary |
| Dr. Alan Brooks Ph.D. | Senior Vice President of Research |
| Katalin Kauser M.D., Ph.D. | Senior Vice President of Translational Biology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Oct 1, 2025 | 8-K | Current Report |